Small molecule · Inhibitor of BRAF · developed by Novartis
Dabrafenib is a small-molecule kinase inhibitor of mutated BRAF kinases, including BRAF V600E, V600K and V600D, and also inhibits wild-type BRAF and CRAF. It blocks the RAS/RAF/MEK/ERK pathway and is studied in melanoma, non-small cell lung cancer, solid tumors and high-grade glioma.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of May 20, 2026). Read the full label for the exact wording, limitations and safety information.
High Grade GliomaMelanomaNon Small Cell Lung CancerRare CancersSolid Tumor
Updated Nov 8, 2026. Something wrong or missing? Report it on the NVS page.
See NVS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
NVS catalysts and pipeline →